Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Navco Pharmaceuticals EBITDA Margin % Related Terms
Navco Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Navco Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F0U vs ZTS, VTRS, NBIX: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Navco Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Navco Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Navco Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Navco Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navco Pharmaceuticals (FRA:F0U) has a EBITDA Margin % of 0.00% as of Mar. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Navco Pharmaceuticals and its competitors.
Is Navco Pharmaceuticals' EBITDA Margin % too high?
Navco Pharmaceuticals' current EBITDA Margin % is 0.00%.
How does Navco Pharmaceuticals' EBITDA Margin % compare to ZTS and VTRS?
Navco Pharmaceuticals' EBITDA Margin % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Navco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Navco Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navco Pharmaceuticals stock overvalued right now?
Navco Pharmaceuticals (FRA:F0U) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Navco Pharmaceuticals (FRA:F0U), the current EBITDA Margin % is 0.00% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Navco Pharmaceuticals Inc is engaged in creating nanotechnology products using computer algorithms. The products are used in various industries like medicine, textiles, chemicals, and additives to combat microorganisms such as viruses and bacteria. Its products include aerosol sprays, hand cleansers, hand creams, and nano BioGuard(tm)-Silver.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F0U has been successfully added to your 
